- Researchers have published results from the first five patients in a clinical trial using focused ultrasound to treat benign pediatric brain tumors.
- The study is ongoing and aims to determine tolerability, safety, and feasibility for treating central brain tumors in adolescents and young adults.
- Early results indicate that focused ultrasound ablation of these tumors is safe.
Researchers using focused ultrasound to treat benign pediatric brain tumors have published initial results from the first five participants enrolled in the clinical trial. The study’s primary aim was to determine tolerability, safety, and feasibility for using focused ultrasound to treat central brain tumors in 10 children or young adults. Four children with hypothalamic hamartoma and one with tuberous sclerosis harboring a subependymal giant cell astrocytoma (SEGA) were treated at Nicklaus Children’s Hospital in Miami, Florida. The procedure was well tolerated with no procedure-related complications. Ablation was successful in the four participants with hypothalamic hamartomas and led to improved seizure control and decreased hyperphagia. No bleeding, electrolyte imbalances, hormone problems, or new neurological deficits occurred. Early results indicate that performing focused ultrasound thermoablation of centrally located brain lesions appears to be safe in this population.
“The series demonstrates that it is possible to use non-ionizing stereotactic surgery to treat pediatric patients with sound, and it may be a safer alternative to conventional radiosurgery,” said Travis Tierney, MD, the first author of the paper.
The study is ongoing, and interested patients can learn more on clinicaltrials.gov.
American Academy of Pediatrics Publishes Article on Focused Ultrasound for Pediatric Diseases February 2022
Momentum Builds for Foundation Pediatrics Program March 2021
Foundation Hosts Pediatric Benign Brain Tumor Workshop March 2021
Focused Ultrasound for Benign Pediatric Brain Tumors: A Case Report May 2020
First Focused Ultrasound Pediatric Brain Tumor Study Begins April 2017